Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy.
JACC: CARDIOONCOLOGY 2019;
1:273-279. [PMID:
34396189 PMCID:
PMC8352120 DOI:
10.1016/j.jaccao.2019.11.006]
[Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 10/30/2019] [Accepted: 11/04/2019] [Indexed: 11/28/2022]
Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development. Assessment of prognosis in ATTR-CM is critical to inform patients about the disease course and guide clinical decisions. This review discusses the evidence behind clinical, biomarker, and imaging findings that inform prognosis in patients with ATTR-CM and can assist providers in the shared decision-making process during management of this disease.
Prognostic factors for ATTR-CM can guide patient expectations and inform clinical decisions.
Clinical features, blood biomarkers, and imaging obtained during workup for ATTR-CM convey prognostic information.
Further studies in determining the incremental value of prognostic factors are warranted.
Collapse